Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma (Q64254749)

2

0 references

Hui Guan

3

0 references

Yang Yu

4

0 references

Jie Lu

5

0 references

Jinming Yu

Journal of Experimental & Clinical Cancer Research

6

0 references

language of work or name

English

0 references

publication date

18 February 2019

7 references

18 June 2019

19 June 2019

25 June 2019

31 July 2019

15 December 2019

9 September 2020

17 October 2022

7 references

18 June 2019

19 June 2019

25 June 2019

31 July 2019

15 December 2019

9 September 2020

17 October 2022

38

0 references

issue

1

0 references

page(s)

87

0 references

copyright license

Creative Commons Attribution 4.0 International

6 references

18 June 2019

19 June 2019

25 June 2019

31 July 2019

15 December 2019

on focus list of Wikimedia project

17 October 2022

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s13046-019-1085-3

0 references

cites work

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

1 reference

12 December 2020

Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts

1 reference

12 December 2020

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

1 reference

12 December 2020

Cloning of mouse Ox40: a T cell activation marker that may mediate T-B cell interactions

1 reference

12 December 2020

Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma.

1 reference

12 December 2020

Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII.

1 reference

12 December 2020

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

1 reference

12 December 2020

Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T cell responses

1 reference

12 December 2020

Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas.

1 reference

12 December 2020

Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells

1 reference

12 December 2020

Human CD4(+)CD25(+) regulatory, contact-dependent T cells induce interleukin 10-producing, contact-independent type 1-like regulatory T cells [corrected].

1 reference

12 December 2020

Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation

1 reference

12 December 2020

Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility

1 reference

12 December 2020

Constitutive EGFR signaling confers a motile phenotype to neural stem cells

1 reference

12 December 2020

Natural and induced CD4+CD25+ cells educate CD4+CD25- cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10.

1 reference

12 December 2020

4-1BB and OX40 stimulation enhance CD8 and CD4 T-cell responses to a DNA prime, poxvirus boost vaccine.

1 reference

12 December 2020

Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients.

1 reference

12 December 2020

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

1 reference

12 December 2020

OX40 (CD134) engagement drives differentiation of CD4+ T cells to effector cells

1 reference

12 December 2020

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

1 reference

12 December 2020

Immune regulation and control of regulatory T cells by OX40 and 4-1BB

1 reference

12 December 2020

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

12 December 2020

The significance of OX40 and OX40L to T-cell biology and immune disease.

1 reference

12 December 2020

PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions

1 reference

12 December 2020

The role of microglia in central nervous system immunity and glioma immunology

1 reference

12 December 2020

Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway

1 reference

12 December 2020

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

1 reference

12 December 2020

Kynurenine is an endothelium-derived relaxing factor produced during inflammation

1 reference

12 December 2020

Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

1 reference

12 December 2020

Different radiosensitivity of CD4(+)CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro

1 reference

12 December 2020

Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model

1 reference

12 December 2020

Improved survival time trends for glioblastoma using the SEER 17 population-based registries

1 reference

12 December 2020

A dialog between glioma and microglia that promotes tumor invasiveness through the CCL2/CCR2/interleukin-6 axis

1 reference

12 December 2020

Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy

1 reference

12 December 2020

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

1 reference

12 December 2020

The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells

1 reference

12 December 2020

Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

1 reference

12 December 2020

Signatures of mutational processes in human cancer

1 reference

12 December 2020

Immune-checkpoint blockade and active immunotherapy for glioma

1 reference

12 December 2020

Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy

1 reference

12 December 2020

Tim-3 on peripheral CD4⁺ and CD8⁺ T cells is involved in the development of glioma

1 reference

12 December 2020

Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.

1 reference

12 December 2020

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

1 reference

12 December 2020

The PD-1/PD-Ls pathway and autoimmune diseases

1 reference

12 December 2020

B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction

1 reference

12 December 2020

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

1 reference

12 December 2020

Immunotherapy for primary brain tumors: no longer a matter of privilege

1 reference

12 December 2020

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

1 reference

12 December 2020

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

1 reference

12 December 2020

Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.

1 reference

12 December 2020

Immune checkpoint blockade therapy: the 2014 Tang Prize in Biopharmaceutical Science

1 reference

12 December 2020

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

1 reference

12 December 2020

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

1 reference

12 December 2020

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

12 December 2020

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

1 reference

12 December 2020

Neoantigens in cancer immunotherapy.

1 reference

12 December 2020

PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer

1 reference

12 December 2020

Structural and functional features of central nervous system lymphatic vessels

1 reference

12 December 2020

TGF-β signaling and its targeting for glioma treatment

1 reference

12 December 2020

4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity

1 reference

12 December 2020

Molecular and cellular insights into T cell exhaustion

1 reference

12 December 2020

Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites

1 reference

12 December 2020

Nivolumab and pembrolizumab as immune-modulating monoclonal antibodies targeting the PD-1 receptor to treat melanoma

1 reference

12 December 2020

PD-L1 expression and prognostic impact in glioblastoma

1 reference

12 December 2020

CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

1 reference

12 December 2020

Immunosuppressive mechanisms in glioblastoma

1 reference

12 December 2020

Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model

1 reference

12 December 2020

Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas

1 reference

12 December 2020

Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma.

1 reference

12 December 2020

Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.

1 reference

12 December 2020

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines

1 reference

12 December 2020

PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.

1 reference

12 December 2020

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

1 reference

12 December 2020

Bioinformatic profiling identifies an immune-related risk signature for glioblastoma

1 reference

12 December 2020

Lymphocyte-activation gene-3, an important immune checkpoint in cancer

1 reference

12 December 2020

Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas

1 reference

12 December 2020

Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors

1 reference

12 December 2020

Radiotherapy combination opportunities leveraging immunity for the next oncology practice

1 reference

12 December 2020

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

1 reference

12 December 2020

Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy

1 reference

12 December 2020

Polymeric nanoparticles promote macrophage reversal from M2 to M1 phenotypes in the tumor microenvironment.

1 reference

12 December 2020

Epidemiology for primary brain tumors: a nationwide population-based study

1 reference

12 December 2020

PD-L1 Expression and Combined Status of PD-L1/PD-1-Positive Tumor Infiltrating Mononuclear Cell Density Predict Prognosis in Glioblastoma Patients

1 reference

12 December 2020

Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma.

1 reference

12 December 2020

Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent.

1 reference

12 December 2020

Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas

1 reference

12 December 2020

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.

1 reference

12 December 2020

The Kynurenine Pathway: A Primary Resistance Mechanism in Patients with Glioblastoma

1 reference

12 December 2020

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

1 reference

12 December 2020

Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression

1 reference

12 December 2020

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.

1 reference

12 December 2020

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.

1 reference

12 December 2020

Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade

1 reference

12 December 2020

Concurrent PD-1 Blockade Negates the Effects of OX40 Agonist Antibody in Combination Immunotherapy through Inducing T-cell Apoptosis

1 reference

12 December 2020

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.

1 reference

12 December 2020

Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples

1 reference

12 December 2020

Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study.

1 reference

12 December 2020

Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy.

1 reference

12 December 2020

Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143.

1 reference

12 December 2020

Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.

1 reference

12 December 2020

Discovery of IDO1 Inhibitors: From Bench to Bedside

1 reference

12 December 2020

IDO1 Inhibition Synergizes with Radiation and PD-1 Blockade to Durably Increase Survival Against Advanced Glioblastoma.

1 reference

12 December 2020

The perfect personalized cancer therapy: cancer vaccines against neoantigens.

1 reference

12 December 2020

Immune checkpoint therapy in liver cancer.

1 reference

12 December 2020

Immunotherapy of Primary Brain Tumors: Facts and Hopes

1 reference

12 December 2020

Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top"

1 reference

12 December 2020

Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

1 reference

12 December 2020

Cancer immunologists scoop medicine Nobel prize

1 reference

12 December 2020

Combination therapy to checkmate Glioblastoma: clinical challenges and advances

1 reference

12 December 2020

Nobel committee honors tumor immunologists

1 reference

12 December 2020

PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer

1 reference

12 December 2020

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

1 reference

12 December 2020